GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Arcus Biosciences Inc.
Arcus Biosciences is a biotech company developing immuno-oncology drugs, often in partnership with the giant Gilead. Its stock price is heavily dependent on clinical trial results and news of their joint programs, which could generate multibillion-dollar payouts.
Share prices of companies in the market segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company developing immuno-oncology drugs, often in partnership with the giant Gilead. We classify it in the Oncology Immunotherapy sector, and the chart below reflects the dynamics of this cutting-edge biotech field.
Broad Market Index - GURU.Markets
Arcus Biosciences is a biopharmaceutical company developing combination immunotherapy for cancer treatment in partnership with Gilead Sciences. It is a component of the GURU.Markets index. The chart below represents the market. See how clinical trial news impacts Arcus shares.
Change in the price of a company, segment, and market as a whole per day
RCUS - Daily change in the company's share price Arcus Biosciences Inc.
The volatility of Arcus Biosciences, an oncology company, reflects the high risks and expectations in the biotech sector. Change_co is an immediate reaction to news about clinical trials, particularly in partnership with Gilead. This metric is the basis for immunotherapy sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Arcus Biosciences, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with RCUS's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Arcus is a biopharmaceutical company developing immuno-oncology drugs. Immuno-oncology is a highly volatile and rapidly growing sector. The chart below reflects the average fluctuations in this sector, helping to assess the risks and performance of Arcus stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Arcus Biosciences Inc.
Arcus is a biotech company specializing in the development of targeted therapies for cancer treatment. Its shares are teetering on the edge of anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Arcus Biosciences, Inc. is a biotech company developing immunotherapies for cancer treatment. Its close partnership with the giant Gilead is a key factor. This chart shows how the market views the potential of its scientific platform and clinical trial results compared to the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Arcus Biosciences is a clinical-stage biotech whose future depends on scientific breakthroughs and its partnership with Gilead. Its stock price is completely disconnected from economic cycles. Its chart reflects scientific events—clinical trial news—rather than macroeconomic data, making it a high-risk bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Arcus Biosciences Inc.
The performance of Arcus, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its oncology drugs, particularly in combination with therapies from its partner Gilead, the success of which determines the realization of the potential of its scientific platform.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Arcus Biosciences, Inc. is an oncology biopharmaceutical company developing combination immunotherapies for cancer treatment. Its sector dynamics, shown in the chart, reflect the high risks of R&D. Against this backdrop, it is possible to assess how its strategic partnership with Gilead Sciences and its broad development pipeline impact its potential for developing new treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Arcus Biosciences is a biopharmaceutical company developing immuno-oncology drugs, often in partnership with the giant Gilead. Its value depends on the success of clinical trials. The overall market chart provides only background, while Arcus's performance is determined by development news, which can trigger sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Arcus Biosciences Inc.
Arcus Biosciences, a biotech company developing immuno-oncology drugs, often in partnership with Gilead, exhibits high volatility. Weekly stock performance depends on news about clinical trials and strategic decisions by its partners, reflecting the risks and potential of R&D.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Arcus Biosciences, like other early-stage biotech companies, often moves in response to overall sector sentiment. The chart allows us to compare its volatility with the industry's overall performance, distinguishing reactions to general news from sharp movements driven by specific clinical trial data.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Arcus Biosciences is a biotech company developing cancer therapies. Its shares exist in a world of their own, driven by research data. The chart clearly demonstrates that Arcus's performance is largely uncorrelated with the market, driven by its unique development news.
Market capitalization of the company, segment and market as a whole
RCUS - Market capitalization of the company Arcus Biosciences Inc.
The Arcus Biosciences chart is a financial map of the next generation of immuno-oncology. The market capitalization of this biotech company, which partners with the giant Gilead, reflects the hopes for its innovative molecules aimed at fighting cancer. Its dynamics are a barometer of progress in clinical trials, where every step can bring the next blockbuster closer.
RCUS - Share of the company's market capitalization Arcus Biosciences Inc. within the market segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company focused on developing combination cancer immunotherapies. Its market capitalization reflects the potential of its broad pipeline and strategic partnership with Gilead. The chart below shows how investors view its potential to create new standards of treatment in oncology.
Market capitalization of the market segment - Oncology immuno-therapy
Arcus Biosciences, in partnership with Gilead, is developing a new generation of oncology drugs. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' high hopes for breakthroughs in cancer immunotherapy.
Market capitalization of all companies included in a broad market index - GURU.Markets
Arcus Biosciences is a biotech company developing combination cancer treatments. Its market capitalization chart tells the story of scientific discovery and strategic partnerships with giants like Gilead. Its dynamics reflect hopes that their approach will become a new standard in oncology.
Book value capitalization of the company, segment and market as a whole
RCUS - Book value capitalization of the company Arcus Biosciences Inc.
For Arcus Biosciences, a biopharmaceutical company, book value represents its R&D capital and laboratory equipment. The chart below shows financial resources for research. Its growth often signifies successful funding for expensive clinical trials.
RCUS - Share of the company's book capitalization Arcus Biosciences Inc. within the market segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company developing cancer therapies. Its primary assets are research and development (R&D) and patents. Its tangible asset share will be low, reflecting its focus on R&D, where the primary physical assets are cutting-edge laboratories rather than large manufacturing facilities.
Market segment balance sheet capitalization - Oncology immuno-therapy
Arcus Biosciences develops immuno-oncology drugs. At the clinical development stage, its main assets are patents and scientific data. A book value chart will show that its value is almost entirely intangible, which is typical for biotech companies focused on future discoveries.
Book value of all companies included in the broad market index - GURU.Markets
Arcus Biosciences' book value is a scientific pipeline for the development of anticancer drugs. The company's assets consist of cutting-edge R&D laboratories, sophisticated research equipment, and capital for numerous clinical trials. The chart shows the size of its resources dedicated to the development of new combinations in immuno-oncology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Arcus Biosciences Inc.
Arcus Biosciences is a biopharmaceutical company focused on immuno-oncology. Its book value is primarily cash. Its market capitalization reflects the potential of its research molecules and its strategic partnership with the giant Gilead. This is a valuation of the science and future breakthroughs in cancer treatment.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company focused on immuno-oncology. Its value is determined by its development pipeline and partnership with Gilead. The chart shows how the market values the potential of its future drugs, placing a significant premium on the value of its lab equipment. This reflects hopes for a breakthrough in cancer treatment.
Market to book capitalization ratio for the market as a whole
Arcus Biosciences is a biopharmaceutical company focused on immuno-oncology. Its value is determined by the potential of its research portfolio, not its tangible assets. The market values the company's hopes for breakthrough drugs. The chart clearly demonstrates the vast gap between market capitalization and book value, typical of biotech.
Debts of the company, segment and market as a whole
RCUS - Company debts Arcus Biosciences Inc.
For Arcus Biosciences, a biopharmaceutical company, debt is a way to accelerate the development of its oncology drugs. This chart shows how the company is raising funds to conduct simultaneous clinical trials of several drug combinations. It's an aggressive strategy aimed at quickly obtaining results and bringing products to market.
Market segment debts - Oncology immuno-therapy
Arcus Biosciences is a biotech company developing immuno-oncology drugs. Biotech financing, especially at the clinical stage, often involves both equity and debt. The chart shows how Arcus's debt strategy compares to its extensive pipeline and partnerships with major pharmaceutical companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Arcus Biosciences Inc.
Arcus Biosciences is a biotech company developing cancer treatments, often in partnership with the giant Gilead. This chart demonstrates its financial discipline. For a company in the clinical development stage, low debt is a sign of stability, allowing it to focus on science rather than servicing creditors.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Arcus Biosciences is a biotech company focused on developing combination immuno-oncology therapies. Its partnership with giant Gilead Sciences provides it with financial support. This chart shows the overall debt load in the sector, allowing one to assess how strategic alliances impact Arcus's financial model compared to independent biotechs.
Debt to book value of all companies in the market
Arcus Biosciences, a biotech company, relies on funding and partnerships. This chart shows the overall market leverage, reflecting the availability of capital. It helps assess how easy or difficult it is for such companies to attract investment from large pharma partners, whose decisions are also influenced by overall macroeconomic conditions.
P/E of the company, segment and market as a whole
P/E - Arcus Biosciences Inc.
Arcus Biosciences develops combination immunotherapies for cancer treatment. This chart reflects investor expectations for its partnership with giant Gilead Sciences. A high score indicates confidence in the company's scientific platform and the potential of its molecules to become part of new standards of cancer treatment, promising billions in royalties and future revenues.
P/E of the market segment - Oncology immuno-therapy
Arcus Biosciences is a representative of the biotech sector. This chart shows the average P/E for the industry. Comparing a company's P/E to this ratio, especially if it's high, indicates how much the market believes in its scientific approach and partnership with Gilead, pricing its potential higher or lower than that of the average biotech.
P/E of the market as a whole
Arcus Biosciences is a biopharmaceutical company focused on developing immuno-oncology drugs. Its future depends on the results of clinical trials and strategic partnerships, such as with Gilead Sciences. This chart shows the market's risk appetite. It allows one to assess whether Arcus is riding the wave of general interest in oncology or whether its valuation is determined by specific scientific data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Arcus Biosciences Inc.
Arcus Biosciences is a biotech company focused on developing combination immuno-oncology therapies. This chart reflects investor expectations for clinical data and partnerships, particularly with Gilead Sciences. The company's valuation is based on the projected future success of its cancer treatments, not current revenue.
%20P%2FE%20Arcus%20Biosciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Arcus-Biosciences-Inc.&v=1772673821604 "Chart of the company's future (projected) P/E Arcus Biosciences Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company developing combination cancer treatments, often in partnership with giant Gilead Sciences. This chart compares Arcus's future profitability expectations with those of the immuno-oncology sector. It demonstrates the level of investor confidence in the success of its clinical programs and the value of its strategic alliance with Gilead.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772673821702 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Arcus Biosciences is a biopharmaceutical company focused on developing immuno-oncology drugs. Financing such long-term and risky projects is highly dependent on the overall investment climate. This graph, reflecting market expectations, is key. Investor optimism provides the capital needed to conduct expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772673821721 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Arcus Biosciences Inc.
Arcus Biosciences is a biopharmaceutical company focused on developing combination cancer treatments. Its financial health is driven by large upfront payments and research funding from its partner, Gilead Sciences. This chart reflects the biotech financial model, where partnership revenues support expensive clinical trials.
Profit of companies in the market segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company focused on developing combination immuno-oncology therapies. This graph, which displays total revenue in the sector, demonstrates how partnerships impact the industry. Arcus' strategic alliances with major pharmaceutical companies to develop new cancer treatments directly impact the growth potential and investment attractiveness of the entire industry.
Overall market profit
Arcus Biosciences develops innovative immunotherapy methods for cancer treatment. The company is at the forefront of science, and its value is determined by the potential of its scientific developments. Its trajectory is not tied to overall economic dynamics, but depends on successes in clinical trials, which could fundamentally change approaches to cancer treatment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Arcus Biosciences Inc.
Arcus Biosciences is a biopharmaceutical company focused on developing combination immuno-oncology therapies. This chart shows analyst forecasts, which are closely tied to clinical trial results and progress in the partnership with Gilead Sciences. Revenue expectations are driven by the potential of their molecules to become new standards of cancer treatment.
%20profit%20of%20the%20company%20Arcus%20Biosciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Arcus-Biosciences-Inc.&v=1772673821962 "Graph of future (projected) profit of the company Arcus Biosciences Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Arcus Biosciences is a biotechnology company developing combination immuno-oncology therapies for the treatment of cancer. This chart demonstrates future revenue expectations for the entire immuno-oncology segment. It allows one to assess how Arcus's scientific approach and its partnerships align with the overall financial outlook for this, one of the hottest areas in pharmaceuticals.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772673821996 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Arcus Biosciences is a biopharmaceutical company focused on immuno-oncology. Like many biotech companies, it prioritizes progress in clinical trials. However, this chart, reflecting market sentiment, is significant. During periods of growth, investors are more inclined to fund risky but promising research, providing Arcus with access to the necessary capital.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772673822020 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Arcus Biosciences Inc.
Arcus Biosciences is a biotech company focused on developing combination immunotherapy drugs for cancer. This metric, which correlates market capitalization with revenue (often from partnerships), reflects expectations for its research. It demonstrates the significant premium investors are paying for the potential of its scientific developments, rather than its current financial performance.
P/S market segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company specializing in the development of combination immuno-oncology therapies. The company aims to create new cancer treatments by targeting various immune system pathways. This chart shows how investors value the oncology sector's revenue, demonstrating the level of confidence in Arcus's scientific platform and its partnerships.
P/S of the market as a whole
Arcus Biosciences is a biopharmaceutical company focused on developing combination immuno-oncology therapies. The company has a strategic partnership with Gilead Sciences. Its valuation is dependent on progress in clinical trials. This chart shows how the market as a whole values its revenue, highlighting how biotech valuations depend on future potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Arcus Biosciences Inc.
Arcus Biosciences is a biopharmaceutical company focused on developing combination immunotherapy drugs for cancer. This chart shows investor estimates of its potential future revenue from drugs in development. It reflects the market's confidence in the success of its clinical trials and its strategic partnership with Gilead.
%20P%2FS%20Arcus%20Biosciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Arcus-Biosciences-Inc.&v=1772673822205 "The graph of the company's future (projected) P/S Arcus Biosciences Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Arcus Biosciences is a biopharmaceutical company focused on developing combination immuno-oncology therapies. This chart compares investor expectations for its future revenue with the sector. A high valuation, often in partnership with Gilead, reflects hopes for the success of its next-generation molecules, while a lower valuation reflects the high risks of clinical trials in this competitive field.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772673822260 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Arcus Biosciences is a biotechnology company developing combination immuno-oncology therapies. The company's future depends on clinical trial results and partnerships with major pharmaceutical companies. This market expectations chart reflects the overall risk appetite of investors in the biotechnology sector and their belief in scientific breakthroughs in cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772673822275 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Arcus Biosciences Inc.
This chart reflects Arcus Biosciences' progress in cancer drug development. As a clinical-stage company, its revenue is generated not from sales but from large upfront and milestone payments through its partnership with the giant Gilead Sciences. This growth reflects the successful progress of their joint research programs.
Sales of companies in the market segment - Oncology immuno-therapy
Arcus Biosciences is a biotechnology company focused on developing combination immuno-oncology therapies. The company's goal is to create more effective cancer treatments. This chart shows the total revenue of the entire oncology drug market, illustrating the enormous commercial potential targeted by Arcus's innovative portfolio.
Overall market sales
Arcus Biosciences, Inc. is a biotechnology company specializing in the development of immuno-oncology drugs. Its financial performance is not dependent on consumer cycles but is driven by clinical trial success. However, the overall economic environment, shown in this chart, influences the investment climate in biotech and the ability to attract capital for expensive R&D.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Arcus Biosciences Inc.
Arcus Biosciences is a biotechnology company focused on developing combination immuno-oncology therapies. Its future revenue depends on the success of clinical trials and strategic partnerships, particularly with Gilead. This chart reflects analyst expectations for the commercial potential of its innovative cancer treatment approaches.
%20sales%20of%20the%20company%20Arcus%20Biosciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Arcus-Biosciences-Inc.&v=1772673822519 "Schedule of future (projected) sales of the company Arcus Biosciences Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Arcus Biosciences is a biopharmaceutical company focused on developing combination immuno-oncology therapies. This chart displays the projected revenue potential from partnerships and future sales of drugs in their portfolio. The data highlights which molecules and combinations, according to analysts, have the highest chance of commercial success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772673822566 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
This chart, reflecting the investment climate in the biotech sector, is critically important for Arcus Biosciences. The company develops immuno-oncology drugs. Its ability to fund lengthy and expensive research depends on the influx of capital into the industry, which directly correlates with overall economic expectations.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772673822713 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Arcus Biosciences Inc.
Arcus Biosciences is a clinical-stage biotech company focused on developing combination cancer treatments. This chart reflects its current status as an investment platform. Profitability is a future goal, dependent on successful clinical trials and potential multibillion-dollar partnerships with major pharma.
Market segment marginality - Oncology immuno-therapy
Arcus Biosciences is a biotechnology company focused on developing combination immuno-oncology therapies. Its profitability depends on the success of clinical trials and strategic partnerships, particularly with Gilead Sciences. This chart shows the average profitability in the pharmaceutical industry and provides context for assessing the potential of Arcus's broad pipeline.
Market marginality as a whole
Arcus Biosciences is a biopharmaceutical company focused on immuno-oncology. Developing new drugs requires significant investment and time. This chart reflects the overall market sentiment and risk appetite. This influences the company's ability to attract funding and partner with major pharma companies to bring its drugs to market.
Employees in the company, segment and market as a whole
Number of employees in the company Arcus Biosciences Inc.
Arcus Biosciences is a biotech company focused on developing combination immuno-oncology therapies. This chart reflects the size of the scientific team conducting research and clinical trials. Growth in the chart indicates progress in developing the drug portfolio and expanding partnerships with major pharmaceutical companies like Gilead.
Share of the company's employees Arcus Biosciences Inc. within the market segment - Oncology immuno-therapy
Arcus Biosciences develops combination immuno-oncology therapies for cancer treatment. Its strategy is based on developing multiple drugs that can work together. This chart shows the percentage of all immuno-oncology researchers Arcus attracts. It indicates the scale of its research programs and its ambition to create a new standard of care.
Number of employees in the market segment - Oncology immuno-therapy
Arcus Biosciences is a biopharmaceutical company focused on developing combination immuno-oncology therapies. This chart reflects activity in the immuno-oncology sector. The growing number of scientists and researchers in this cutting-edge field demonstrates the intense competition and significant investment in finding new ways to fight cancer, a niche in which Arcus is seeking to carve out its niche.
Number of employees in the market as a whole
Arcus Biosciences is a biopharmaceutical company developing combination cancer treatments. Their value and growth are driven by clinical trial results and partnerships with major pharmaceutical companies. This chart reflects macroeconomics, but for Arcus, the reality is shaped by laboratories and cancer centers, where demand for their scientists is generated.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Arcus Biosciences Inc. (RCUS)
Arcus Biosciences is a biopharmaceutical company focused on immuno-oncology. Its value is based almost entirely on the potential of its R&D pipeline. This chart demonstrates that investors are placing a premium on the intellectual property generated by a small team of top-notch scientists, resulting in an extremely high valuation per employee.
%20of%20the%20company%20Arcus%20Biosciences%20Inc.%20(RCUS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Arcus-Biosciences-Inc.-RCUS&v=1772673823300 "Chart of market capitalization per employee (in thousands of dollars) of the company Arcus Biosciences Inc. (RCUS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company focused on developing immuno-oncology drugs, often in partnership with Gilead. Their value lies in their R&D pipeline and partnerships. This chart reflects the high market valuation of their scientific potential based on their relatively small research team.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772673823332 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Arcus Biosciences is a biopharmaceutical company focused on developing combination cancer treatments. In immuno-oncology, valuation is determined by the potential for scientific breakthroughs. This chart demonstrates the company's enormous market value per employee, as investors bet on the future success of drugs developed by its highly qualified scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772673823359 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Arcus Biosciences Inc. (RCUS)
Arcus Biosciences is a biotech company working in the hot field of immuno-oncology, developing drugs that help the immune system attack cancer. This chart reflects their status: they are an "R&D company" that spends significant (negative profit) resources on each scientist to advance their molecules through clinical trials.
%20Chart%20Arcus%20Biosciences%20Inc.%20(RCUS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Arcus-Biosciences-Inc.-RCUS&v=1772673823364 "Company Profit Per Employee (in thousands of dollars) Chart Arcus Biosciences Inc. (RCUS)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Arcus Biosciences is a clinical-stage biotech company developing "immunotherapy" (antibodies) for cancer treatment (in partnership with Gilead). This chart shows the benchmark for the "Biotech sector." In this industry, the average profit per employee is typically deeply negative. The benchmark is determined not by "profit," but by the "burn rate" of the R&D budget.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772673823384 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Arcus Biosciences is a biotech company focused on immuno-oncology. They develop combination cancer treatments, often in partnership with giants like Gilead. It's an R&D business that lives in the lab. This chart helps us understand how this model, where all value is created by the intellectual labor of a small group of scientists, differs from the economic average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772673823403 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Arcus Biosciences Inc. (RCUS)
Arcus Biosciences is a biotech company developing immuno-oncology drugs. While in clinical trials, its revenue per employee comes primarily from partnerships with major pharmaceutical companies. This chart shows these upfront and milestone payments, which fund further development before market entry.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Arcus-Biosciences-Inc.-RCUS&v=1772673823438 "Sales chart per company employee Arcus Biosciences Inc. (RCUS)")
Sales per employee in the market segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company focused on immuno-oncology (cancer treatment through immune activation), often partnering with Gilead. It's an R&D company. This chart reflects their stage of development. Revenue (if any) is primarily from partner fees, not sales. The productivity of their scientists lies in advancing molecules through clinical trials.
Sales per employee for the market as a whole
Arcus Biosciences (RCUS) is a biotech company focused on developing cancer immunotherapies, often in combination with other drugs. They have a strategic partnership with Gilead. This graph is typical for a biotech company in the R&D stage. Revenue, if any, comes not from sales but from large upfront and milestone payments from partners (like Gilead). This metric reflects the intensive research phase, not sales performance.
Short shares by company, segment and market as a whole
Shares shorted by company Arcus Biosciences Inc. (RCUS)
Arcus Biosciences is a biotech company working in the hot field of immuno-oncology. They develop combination cancer treatments, often in partnership with giant Gilead Sciences. This chart shows bearish bets. Skeptics may doubt the success of their clinical programs or that their drugs will be able to outperform existing market leaders, such as Merck's Keytruda.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Arcus-Biosciences-Inc.-RCUS&v=1772673823673 "Short Shares Chart for the Company Arcus Biosciences Inc. (RCUS)")
Shares shorted by market segment - Oncology immuno-therapy
Arcus Biosciences (RCUS) is a biotech company partnering with Gilead. They are developing immuno-oncology drugs targeting novel targets. This chart summarizes short positions across the entire immunotherapy segment. A rising indicator signals that investors are generally skeptical of this area, possibly due to intense competition or recent trial failures.
Shares shorted by the overall market
Arcus (RCUS) is a clinical-stage biotech (oncology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives RCUS of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Arcus Biosciences Inc. (RCUS)
Arcus Biosciences is a biotech company working in the hot field of immuno-oncology, in close partnership with Gilead. They are targeting key cancer checkpoints. This chart measures the level of confidence in their R&D platform. It shows when the stock is "overbought" based on trial data or "oversold" due to setbacks or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Arcus-Biosciences-Inc.-RCUS&v=1772673823836 "RSI 14 indicator chart for the company's stock Arcus Biosciences Inc. (RCUS)")
RSI 14 Market Segment - Oncology immuno-therapy
Arcus Biosciences is a biotech company focused on immuno-oncology. They are developing combination cancer treatments, including TIGIT inhibitors (in partnership with Gilead). This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated by expectations of clinical success.
RSI 14 for the overall market
Arcus Biosciences (RCUS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RCUS (Arcus Biosciences Inc.)
Arcus Biosciences is a biotech company focused on developing immuno-oncology drugs, often in partnership with the giant Gilead. This chart shows the average target price. Analysts' forecasts are based on clinical data, the potential of drug combinations, and the value of the strategic alliance with Gilead.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RCUS-Arcus-Biosciences-Inc.&v=1772673824018 "A chart showing analyst consensus forecasts for the expected stock price. RCUS (Arcus Biosciences Inc.)")
The difference between the consensus estimate and the actual stock price RCUS (Arcus Biosciences Inc.)
Arcus Biosciences (RCUS) is an oncology company developing immunotherapies (competitors to Keytruda), often in partnership with giant Gilead Sciences. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their clinical programs and the strength of their partnership with Gilead.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RCUS-Arcus-Biosciences-Inc.&v=1772673824037 "A chart showing the difference between the consensus forecast and the actual stock price. RCUS (Arcus Biosciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Arcus Biosciences is a biopharmaceutical company developing a new generation of immuno-oncology drugs in partnership with the giant Gilead. This chart shows analysts' overall expectations for the cancer immunotherapy sector. It reflects whether experts believe in the success of combinations of new drugs with existing ones.
Analysts' consensus forecast for the overall market share price
Arcus Biosciences (RCUS) is an R&D partner of Gilead. They're a biotech developing immuno-oncology (TIGIT). They're burning cash. This chart, reflecting expert expectations, is their risk appetite. When the market is pessimistic, investors flee cash-burning, pre-profit biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Arcus Biosciences Inc.
Arcus Biosciences is a biotech company operating in the immuno-oncology (IO) hotspot. Their main bet is their alliance with Gilead and their molecule targeting TIGIT (a PD-1 competitor). This chart is a pure indicator of their R&D pipeline. It likely aggregates their clinical trial data (especially for TIGIT) and market confidence in their combo approach to cancer treatment.
AKIMA Market Segment Index - Oncology immuno-therapy
Arcus Biosciences (RCUS) is a clinical-stage biotech focused on cancer immunotherapy (a competitor of Gilead, which is their partner); the company is developing a new generation of oncology drugs (anti-TIGIT). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D platform (and partnership with Gilead) differentiate RCUS from the average pharma company?
The AKIM Index for the overall market
Arcus Biosciences is a biotech company developing cancer immunotherapy in partnership with Gilead Sciences. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this resource-rich R&D company compares to the broader economic trends affecting the healthcare sector.
